ClinicalTrials.gg
Not yet recruitingNCT06926647Updated Apr 29, 2025

A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

An observational study in HBV and Chronic Hepatitis b, sponsored by Beijing 302 Hospital. Not yet recruiting at 85 sites in China. Open to participants aged 1 Year to 13 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Beijing 302 Hospital · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
1 Year to 13 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Hepatitis B, Chronic by Beijing 302 Hospital — 3 open to participants now, 5 under way, none of them phase 3. Hepatitis B, Chronic · Beijing 302 Hospital.

Started
2025
the only one that year
Observational
Only one
of the 10
Registered
9th of 10
by date

Among the 10 studies in Hepatitis B, Chronic by Beijing 302 Hospital, this one is the only one that started in 2025, is the only observational one, and was the 9th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 10 studies in Hepatitis B, Chronic by Beijing 302 Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 1 Year to 13 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hepatitis B, Chronic by Beijing 302 Hospital, or all of them as a file.
02

Study summary

This is a multicenter, prospective, real-world study. The study plans to include a total of 2000 patients who meet the inclusion and exclusion criteria, consisting of 1600 treatment-naive patients and 400 treatment-experienced patients. The effectiveness and safety of different treatment strategies will be evaluated in children aged 1-12 years with treatment-naive and treatment-experienced chronic hepatitis B (CHB) and chronic HBV infection.

03

Conditions studied

  • HBV
  • Chronic Hepatitis b

Browse trials for

Keywords

  • Nucleos(t)ide Analogues(NAs)
  • Interferon alpha(IFNα)
04

Who can participate

Ages eligible
1 Year to 13 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients provided by hospitals from various centers across the country are standardized in English translation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Initial Treatment Group:

    1. The guardian understands and signs the form (both parents must sign), and adheres to the relevant requirements of this study. If the participant is 8 years old or older, they must also sign the informed consent form. For participants under 8 years old who can express consent, their consent must be clearly documented.
    2. Age: ≥1 year and \<13 years, either sex;
    3. Positive for and/or HBV DNA for more than 6 months;
    4. No prior antiviral treatment.
  • Treated Group:

    1. The guardian understands and signs the informed consent form (both parents must sign), and adheres to the relevant requirements of this study. If the participant is 8 years old or older, they must also sign the informed consent form. For participants under 8 years old who can express consent, their consent must be clearly documented.
    2. Age: ≥3 years and \<13 years, either sex;
    3. Previously diagnosed with chronic hepatitis B and received antiviral treatment with NAs for more than 1 year and currently on treatment;
    4. No history of IFNα use in the past 6 months;
    5. Negative for HBV DNA;
    6. HBsAg quantification \<10,000 IU/ml (HBsAg can be negative in the drug discontinuation observation group);
    7. The drug discontinuation observation group must also achieve negative HBV DNA and HBeAg seroconversion for at least 1 year (based on continuous results from three consecutive reviews), and HBsAg \<10,000 IU/ml; NAs will be discontinued after enrollment.

Exclusion criteria

Exclusion Criteria:

  • 1.In the interferon group, blood white blood cell count \<3.5×10\^9/L, or count \<80×10\^9/L, or prothrombin activity \<60%, or total >34μmol/L, or serum albumin \<35g/L, or serum creatinine >133μmol/L; 2.Coexistence of other active infections; 3. Coexistence of other chronic liver diseases or active liver diseases, such as liver disease, drug-induced liver injury, Wilson's disease, decompensated cirrhosis, liver cancer; 4. Coexistence of other severe systemic diseases or malignant tumors, etc.; 5. History of allergy to nucleoside analogues or interferon; 6. Subjects whom the investigator deems to have poor compliance, unable or unwilling to provide , or unable to adhere to the study requirements, or other conditions not suitable for participation in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Initial Treatment Cohort 1

    Drug: Nucleos(t)ide Analogues · Drug: Interferon alfa · Drug: NAs combined with IFNα · Other: comparative observation

  • Previously Treated Cohort 1

    Drug: Nucleos(t)ide Analogues · Drug: NAs combined with IFNα · Other: drug withdrawal observation

Interventions

  • Administer NAs \[LAM, ETV, TDF, TAF (TAF preferred for those aged 6 years and older)\] continuously for 48 weeks based on age.

  • IFNα monotherapy for 48 weeks (select conventional IFNα for ages ≥1 and \<3 years, select PEG-IFNα-2b for ages ≥3 years)

  • DrugNAs combined with IFNα

    Receive NAs combined with IFNα treatment for 48 weeks.

  • Othercomparative observation

    Blank control observation for 48 weeks.

  • Otherdrug withdrawal observation

    This group is the drug withdrawal observation group, which will strictly monitor virological indicators and biochemical results, and will reinitiate antiviral treatment if necessary based on antiviral treatment standards and the willingness of the child (or family members)

06

What researchers measure

Primary outcomes

  1. HBsAg seroconversion rate

    Time frame: Week 48,96

Secondary outcomes

  1. HBV DNA negative conversion rate

    Time frame: Week 48,96

  2. HBeAg negative conversion rate

    Time frame: Week 48,96

  3. HBeAg seroconversion rate

    Time frame: Week 48,96

  4. HBsAg seroconversion rate

    Time frame: Week 48,96

  5. ALT normalization rate

    Time frame: Week 48,96

07

Study locations

85 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Dec 2028, 43 months later.

Of 71 observational studies under Hepatitis B, Chronic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 99. This study's planned 43 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 14, 2025
StartEst.
May 1, 2025
Primary completionEst.
Dec 15, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06926647
Lead sponsor
Beijing 302 Hospital
Responsible party
Fu-Sheng Wang (Chief physician, Beijing 302 Hospital) — Principal investigator
First posted
Apr 14, 2025
Start date
May 1, 2025 (estimated)
Primary completion
Dec 15, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 29, 2025

Study contacts

Fusheng Wang
Contact
13601162078@163.com
13601162078
Fusheng Wang
study director · Fifth Medical Center of Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion